Asahi shares mark weekly slide after cyberattack halts production
Cel-Sci Corp (NYSE:CVM) stock has touched a new 52-week low, sinking to $0.33, as the biotechnology firm faces a challenging period marked by a significant downturn in its market valuation. InvestingPro data reveals the company’s overall financial health score stands at a concerning 1.33, labeled as "WEAK," with negative EBITDA of $24.6 million in the last twelve months. Over the past year, the company’s shares have plummeted, reflecting an 83.22% decrease from their previous positions. This sharp decline underscores investor concerns and the hurdles the company has encountered, which have severely impacted its stock performance on the trading front. Despite the current downturn, analyst price targets range from $6 to $10, with a relatively low beta of 0.69. The 52-week low represents a critical juncture for Cel-Sci Corp as it navigates through a phase of investor skepticism and seeks to regain market confidence. InvestingPro subscribers can access 8 additional key insights about CVM’s financial outlook.
In other recent news, CEL-SCI Corporation has announced the commencement of its Confirmatory Registration Study for Multikine, aimed at treating head and neck cancer. This follows the submission of the final clinical protocol to the FDA, with the study targeting patients with newly diagnosed resectable stage 3 and 4 head and neck cancer. The previous Phase 3 trial showed a significant increase in 5-year survival rates, from 45% to 73%, for those treated with Multikine. The study is expected to enroll 212 patients by the second quarter of 2026, with early tumor response data being used to seek accelerated approval. Additionally, CEL-SCI has completed a $5 million stock offering, which will support the continued development of Multikine and other corporate purposes. The offering consisted of over 16 million shares of common stock at $0.31 per share, facilitated by ThinkEquity as the sole placement agent. The funds raised will aid in the company’s ongoing efforts to enhance immune response in cancer patients. These developments come as CEL-SCI continues its work on its flagship treatment, Multikine, which has received Orphan Drug designation from the FDA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.